Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19715516 | 0.84 | ALDH1A1 (0.47) | DNM1ALDH1A1KDM4ESMN1; SMN2CARM1 | |
| SCHEMBL83748 | 0.81 | PNP (0.43) | ALDH1A1KDM4ETSHRCNR2MEN1 | |
| SCHEMBL13657504 | 0.81 | PNP (0.43) | ALDH1A1KDM4ETSHRCNR2MEN1 | |
| SCHEMBL3439186 | 0.81 | PNP (0.43) | ALDH1A1KDM4ETSHRCNR2MEN1 | |
| SCHEMBL721952 | 0.80 | DNM1 (0.59) | DNM1ALDH1A1KDM4ESMN1; SMN2CARM1 | |
| SCHEMBL17824014 | 0.80 | DNM1 (0.59) | DNM1ALDH1A1KDM4ESMN1; SMN2CARM1 | |
| SCHEMBL17823521 | 0.80 | DNM1 (0.59) | DNM1ALDH1A1KDM4ESMN1; SMN2CARM1 | |
| SCHEMBL25234019 | 0.79 | ALDH1A1 (0.50) | DNM1ALDH1A1KDM4ESMN1; SMN2CARM1 | |
| Hydrochloric Acid SCHEMBL9874632 | 0.79 | ALDH1A1 (0.52) | DNM1ALDH1A1KDM4ESMN1; SMN2CARM1 | |
| SCHEMBL9700093 | 0.77 | DNM1 (0.55) | DNM1ALDH1A1KDM4ESMN1; SMN2CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023860-B2 | Pro-drugs for controlled release of biologically active compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023860-B2 | Pro-drugs for controlled release of biologically active compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023860-B2 | Pro-drugs for controlled release of biologically active compounds | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | 3I, LP | 2009-05-28 | — | — | US | disclosed |
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | 3I, LP | 2009-05-28 | — | — | US | disclosed |
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | 3I, LP | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137618-A1 | PRO-DRUGS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS | CRH, FURIN, PEPD | DNM1 3658/4885ALDH1A1 2963/4885KDM4E 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.